Eukaryotic Translation Elongation Factor 1-Alpha 1 Inhibits p53 and p73 Dependent Apoptosis and Chemotherapy Sensitivity

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Blanch, Alvaro ^a   Robinson, Fiona ^a   Watson, Ian R ^a   Cheng, Lynn S ^a   Irwin, Meredith S ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CASPASE 7; CISPLATIN; DOXORUBICIN; ELONGATION FACTOR 1 ALPHA1; ELONGATION FACTOR 1ALPHA; ETOPOSIDE; PROTEIN P53; PROTEIN P73; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STABILITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CISPLATIN; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HELA CELLS; HUMANS; NUCLEAR PROTEINS; PEPTIDE ELONGATION FACTOR 1; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EUKARYOTA;

EID: 84879144366     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066436     Document Type: Article

References (58)

1. Murray-Zmijewski F, Lane DP, Bourdon JC, (2006) p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13: 962-972.
2. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, et al. (1998) Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 18: 6316-6324.
3. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, et al. (2000) An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289: 304-306.
4. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, et al. (2002) DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196: 765-780.
5. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622.
6. Irwin MS, (2004) Family feud in chemosensitvity: p73 and mutant p53. Cell Cycle 3: 319-323.
7. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW, (2006) p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9: 45-56.
8. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, et al. (2010) Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 24: 549-560.
9. Aylon Y, Oren M, (2007) Living with p53, dying of p53. Cell 130: 597-600.
10. Collavin L, Lunardi A, Del Sal G, (2010) p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 17: 901-911.
11. Hershey JW, (1991) Translational control in mammalian cells. Annu Rev Biochem 60: 717-755.
12. Thornton S, Anand N, Purcell D, Lee J, (2003) Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 81: 536-548.
13. Tatsuka M, Mitsui H, Wada M, Nagata A, Nojima H, et al. (1992) Elongation factor-1 alpha gene determines susceptibility to transformation. Nature 359: 333-336.
14. Kato MV, Sato H, Nagayoshi M, Ikawa Y, (1997) Upregulation of the elongation factor-1alpha gene by p53 in association with death of an erythroleukemic cell line. Blood 90: 1373-1378.
15. Lamberti A, Caraglia M, Longo O, Marra M, Abbruzzese A, et al. (2004) The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids 26: 443-448.
16. Al-Maghrebi M, Anim JT, Olalu AA, (2005) Up-regulation of eukaryotic elongation factor-1 subunits in breast carcinoma. Anticancer Res 25: 2573-2577.
17. Chuang SM, Chen L, Lambertson D, Anand M, Kinzy TG, et al. (2005) Proteasome-mediated degradation of cotranslationally damaged proteins involves translation elongation factor 1A. Mol Cell Biol 25: 403-413.
18. Gross SR, Kinzy TG, (2005) Translation elongation factor 1A is essential for regulation of the actin cytoskeleton and cell morphology. Nat Struct Mol Biol 12: 772-778.
19. Grant AG, Flomen RM, Tizard ML, Grant DA, (1992) Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells. Int J Cancer 50: 740-745.
20. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, et al. (1997) Gene expression profiles in normal and cancer cells. Science 276: 1268-1272.
21. Xie D, Jauch A, Miller CW, Bartram CR, Koeffler HP, (2002) Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex FISH and comparative genomic hybridization. Int J Oncol 21: 499-507.
22. Mohler JL, Morris TL, Ford OH 3rd, Alvey RF, Sakamoto C, et al. (2002) Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate 51: 247-255.
23. de Wit NJ, Burtscher HJ, Weidle UH, Ruiter DJ, van Muijen GN, (2002) Differentially expressed genes identified in human melanoma cell lines with different metastatic behaviour using high density oligonucleotide arrays. Melanoma Res 12: 57-69.
24. Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, et al. (2000) Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer 83: 1047-1054.
25. Edmonds BT, Wyckoff J, Yeung YG, Wang Y, Stanley ER, et al. (1996) Elongation factor-1 alpha is an overexpressed actin binding protein in metastatic rat mammary adenocarcinoma. J Cell Sci 109 (Pt 11) (): 2705-2714.
26. Duttaroy A, Bourbeau D, Wang XL, Wang E, (1998) Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha. Exp Cell Res 238: 168-176.
27. Chen E, Proestou G, Bourbeau D, Wang E, (2000) Rapid up-regulation of peptide elongation factor EF-1alpha protein levels is an immediate early event during oxidative stress-induced apoptosis. Exp Cell Res 259: 140-148.
28. Borradaile NM, Buhman KK, Listenberger LL, Magee CJ, Morimoto ET, et al. (2006) A critical role for eukaryotic elongation factor 1A-1 in lipotoxic cell death. Mol Biol Cell 17: 770-778.
29. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, et al. (2007) C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ 14: 952-962.
30. Kobayashi Y, Yonehara S, (2009) Novel cell death by downregulation of eEF1A1 expression in tetraploids. Cell Death Differ 16: 139-150.
31. Talapatra S, Wagner JD, Thompson CB, (2002) Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis. Cell Death Differ 9: 856-861.
32. Pecorari L, Marin O, Silvestri C, Candini O, Rossi E, et al. (2009) Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. Mol Cancer 8: 58.
33. Kim J, Namkung W, Yoon JS, Jo MJ, Lee SH, et al. (2009) The role of translation elongation factor eEF1A in intracellular alkalinization-induced tumor cell growth. Lab Invest 89: 867-874.
34. Selga E, Oleaga C, Ramirez S, de Almagro MC, Noe V, et al. (2009) Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med 1: 83.
35. Ruest LB, Marcotte R, Wang E, (2002) Peptide elongation factor eEF1A-2/S1 expression in cultured differentiated myotubes and its protective effect against caspase-3-mediated apoptosis. J Biol Chem 277: 5418-5425.
36. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
37. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, et al. (2000) Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645-648.
38. Chung J, Lau J, Cheng LS, Grant RI, Robinson F, et al. (2010) SATB2 augments DeltaNp63alpha in head and neck squamous cell carcinoma. EMBO Rep 11: 777-783.
39. Lau L, Hansford LM, Cheng LS, Hang M, Baruchel S, et al. (2007) Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 26: 1920-1931.
40. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, et al. (2003) Chemosensitivity linked to p73 function. Cancer Cell 3: 403-410.
41. Khacho M, Mekhail K, Pilon-Larose K, Pause A, Cote J, et al. (2008) eEF1A is a novel component of the mammalian nuclear protein export machinery. Mol Biol Cell 19: 5296-5308.
42. Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS, (2006) Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 281: 34096-34103.
43. Balint E, Bates S, Vousden KH, (1999) Mdm2 binds p73 alpha without targeting degradation. Oncogene 18: 3923-3929.
44. Frum R, Busby SA, Ramamoorthy M, Deb S, Shabanowitz J, et al. (2007) HDM2-binding partners: interaction with translation elongation factor EF1alpha. J Proteome Res 6: 1410-1417.
45. Momand J, Zambetti GP, Olson DC, George D, Levine AJ, (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
46. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, et al. (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779-791.
47. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC, et al. (2005) The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24: 836-848.
48. Ohtsuka T, Ryu H, Minamishima YA, Ryo A, Lee SW, (2003) Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene 22: 1678-1687.
49. Qian Y, Jung YS, Chen X, (2012) DEC1 and MIC-1: new players of p53-dependent cell fate decision. Cell Cycle 11: 3525-3526.
50. Li BD, Gruner JS, Abreo F, Johnson LW, Yu H, et al. (2002) Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 235: 732-738 discussion 738-739.
51. Nathan CO, Sanders K, Abreo FW, Nassar R, Glass J, (2000) Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications. Cancer Res 60: 3599-3604.
52. Rosenwald IB, Hutzler MJ, Wang S, Savas L, Fraire AE, (2001) Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 92: 2164-2171.
53. Gopalkrishnan RV, Su ZZ, Goldstein NI, Fisher PB, (1999) Translational infidelity and human cancer: role of the PTI-1 oncogene. Int J Biochem Cell Biol 31: 151-162.
54. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
55. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, et al. (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 103: 1888-1893.
56. Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, et al. (2006) Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 66: 9646-9655.
57. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, et al. (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61-66.
58. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, et al. (2006) MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107: 4109-4114.